WO2004024060A3 - Metalloproteinase inhibitors and intermediates for preparation thereof - Google Patents

Metalloproteinase inhibitors and intermediates for preparation thereof Download PDF

Info

Publication number
WO2004024060A3
WO2004024060A3 PCT/SE2003/001406 SE0301406W WO2004024060A3 WO 2004024060 A3 WO2004024060 A3 WO 2004024060A3 SE 0301406 W SE0301406 W SE 0301406W WO 2004024060 A3 WO2004024060 A3 WO 2004024060A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
intermediates
metalloproteinase inhibitors
pharmaceutical compositions
therapy
Prior art date
Application number
PCT/SE2003/001406
Other languages
French (fr)
Other versions
WO2004024060A2 (en
Inventor
Balint Gabos
Michael Lundkvist
Af Rosenschoeld Magnus Munck
Igor Shamovsky
Original Assignee
Astrazeneca Ab
Balint Gabos
Michael Lundkvist
Af Rosenschoeld Magnus Munck
Igor Shamovsky
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Balint Gabos, Michael Lundkvist, Af Rosenschoeld Magnus Munck, Igor Shamovsky filed Critical Astrazeneca Ab
Priority to AU2003258941A priority Critical patent/AU2003258941A1/en
Publication of WO2004024060A2 publication Critical patent/WO2004024060A2/en
Publication of WO2004024060A3 publication Critical patent/WO2004024060A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Abstract

The invention provides compounds of formula, in which X, Y, R1, G1 and G2 have the meanings defined in the specification; processes for their preparation; pharmaceutical compositions containing them; a process for preparing the pharmaceutical compositions; and their use in therapy.
PCT/SE2003/001406 2002-09-11 2003-09-10 Metalloproteinase inhibitors and intermediates for preparation thereof WO2004024060A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003258941A AU2003258941A1 (en) 2002-09-11 2003-09-10 Metalloproteinase inhibitors and intermediates for preparation thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0202692-0 2002-09-11
SE0202692A SE0202692D0 (en) 2002-09-11 2002-09-11 Compounds

Publications (2)

Publication Number Publication Date
WO2004024060A2 WO2004024060A2 (en) 2004-03-25
WO2004024060A3 true WO2004024060A3 (en) 2004-06-24

Family

ID=20288962

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2003/001406 WO2004024060A2 (en) 2002-09-11 2003-09-10 Metalloproteinase inhibitors and intermediates for preparation thereof

Country Status (3)

Country Link
AU (1) AU2003258941A1 (en)
SE (1) SE0202692D0 (en)
WO (1) WO2004024060A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (en) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0103710D0 (en) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
SE0202539D0 (en) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US8013006B2 (en) 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000762A (en) 2004-07-22 2007-04-02 Ptc Therapeutics Inc Thienopyridines for treating hepatitis c.
US7858666B2 (en) 2007-06-08 2010-12-28 Mannkind Corporation IRE-1α inhibitors

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2745875A (en) * 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
GB1117616A (en) * 1964-09-23 1968-06-19 Warner Lambert Pharmaceutical Process for preparing 1-(p-acetylphenyl)-2-(2,2-dichloroacetamido)-1,3-propanediol
WO1993020053A1 (en) * 1992-03-27 1993-10-14 Yamanouchi Pharmaceutical Co., Ltd. Pyridylserine derivative
EP1191024A1 (en) * 2000-09-22 2002-03-27 Harald Tschesche Thiadiazines and their use as inhibitors of metalloproteinases
WO2002074750A1 (en) * 2001-03-15 2002-09-26 Astrazeneca Ab Metalloproteinase inhibitors
WO2002074752A1 (en) * 2001-03-15 2002-09-26 Astrazeneca Ab Metalloproteinase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2745875A (en) * 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
GB1117616A (en) * 1964-09-23 1968-06-19 Warner Lambert Pharmaceutical Process for preparing 1-(p-acetylphenyl)-2-(2,2-dichloroacetamido)-1,3-propanediol
WO1993020053A1 (en) * 1992-03-27 1993-10-14 Yamanouchi Pharmaceutical Co., Ltd. Pyridylserine derivative
EP1191024A1 (en) * 2000-09-22 2002-03-27 Harald Tschesche Thiadiazines and their use as inhibitors of metalloproteinases
WO2002074750A1 (en) * 2001-03-15 2002-09-26 Astrazeneca Ab Metalloproteinase inhibitors
WO2002074752A1 (en) * 2001-03-15 2002-09-26 Astrazeneca Ab Metalloproteinase inhibitors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CROCE PIERO DALLA ET AL.: "Stereoselective aldol addition of a chiral glycine enolate synthon to heteroaromatic aldehydes", HETEROCYCLES, vol. 52, no. 3, 2000, pages 1337 - 1344 *
DATABASE ACS [online] SAKAMOTO SHUICHI ET AL.: "Preparation of pyridylserine derivatives as psychotropics", XP002973688, accession no. STN Database accession no. 1994:299315 *
RIICHIRO NAKAJIMA ET AL.: "The utility of 4-(2-thinyl)pyridines as a derivatization reagent for hplc and ce", ANALYTICAL SCIENCES, vol. 7, no. SUPPL., 1991, pages 177 - 180, XP002973684 *
SEI-ICHI SAITO ET AL.: "A new synthesis of deglyco-bleomycin A2 aiming at the total synthesis of bleomycin", TETRAHEDRON LETTERS, vol. 23, no. 5, 1982, pages 529 - 532, XP002973686 *
TAKASHI OWA ET AL.: "Man-designed bleomycins: significance of the binding sites as enzyme models and of the stereochemistry of the linker moiety", TETRAHEDRON, vol. 48, no. 7, 1992, pages 1193 - 1208, XP002973683 *
TOSHIAKI MIYAKE ET AL.: "Studies on glycosylation of erythro-beta-hydroxy-L-histidine. A key step of bleomycin total synthesis", BULL. CHEM. SOC. JPN., vol. 59, 1986, pages 1387 - 1395, XP002973685 *
WHITTAKER MARK ET AL.: "Design and therapeutic application of matrix metalloproteinase inhibitors", CHEM. REV., vol. 99, 1999, pages 2735 - 2776, XP002943426 *

Also Published As

Publication number Publication date
WO2004024060A2 (en) 2004-03-25
AU2003258941A1 (en) 2004-04-30
SE0202692D0 (en) 2002-09-11
AU2003258941A8 (en) 2004-04-30

Similar Documents

Publication Publication Date Title
SE0202539D0 (en) Compounds
SE0200920D0 (en) Novel compounds
SE0302811D0 (en) Novel compounds
SE0104140D0 (en) Novel Compounds
WO2004074244A3 (en) Pyrimidine compounds
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
HK1099751A1 (en) Triazolone derivatives as mmp inhibitors for the treatment of asthma and copd
TW200800999A (en) Novel compounds
WO2005046603A3 (en) Pyridine compounds
TW200508214A (en) Novel compounds
SE0300480D0 (en) Novel compounds
CA2441313A1 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
WO2006039718A3 (en) Aryl nitrogen-containing bicyclic compounds and their use as kinase inhibitors
TW200635917A (en) Novel compounds
WO2003095455A3 (en) Substituted pyrazolopyrimidines
TW200635916A (en) Compounds
MY128924A (en) Novel compounds
WO2005085236A3 (en) Caspase inhibitors and uses thereof
WO2004100865A3 (en) New benzimidazole derivatives
TW200604197A (en) New compounds
WO2003018553A8 (en) Oral antidiabetic agents
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
WO2004069160A3 (en) Chemical compounds
WO2004024060A3 (en) Metalloproteinase inhibitors and intermediates for preparation thereof
WO2003054001A3 (en) Method for preparing echinocandin derivatives and their compositions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP